217 results on '"San Martin, Javier"'
Search Results
2. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)
3. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
4. A survey on the perception of the specialty of Endocrinology and Nutrition among students preparing for the entrance exam for medical specialty training in Spain
5. Comprehensive approach to people with type 2 diabetes. Diabetes Knowledge Area of the Spanish Society of Endocrinology and Nutrition
6. Abordaje integral de las personas con diabetes tipo 2. Área de Conocimiento de Diabetes de la Sociedad Española de Endocrinología y Nutrición
7. Abstract 17120: ARO-ANG3, an Investigational RNAi Therapeutic, Silences the Expression of ANGPTL3 and Decreases Atherogenic Lipoproteins in Patients With Mixed Dyslipidemia: ARCHES-2 Study Results
8. Abstract 17091: ARO-APOC3, an Investigational RNAi Therapeutic, Silences APOC3 and Reduces Atherosclerosis-Associated Lipoproteins in Patients With Mixed Dyslipidemia: MUIR Study Results
9. A novel photoanaerobic process as a feasible alternative to the traditional aerobic treatment of refinery wastewater
10. Adoption of measures to mitigate the impact of COVID-19: In search of a Hofstedian explanation for patterns among individual countries and country clusters
11. Executive summary of the consensus statement of: Clinical recommendations for sport practice in people with diabetes (RECORD Guide). Update 2021. Diabetes Mellitus Area of the Spanish Society of Endocrinology and Nutrition (SEEN)
12. Resumen ejecutivo del documento de consenso sobre: recomendaciones clínicas para la práctica del deporte en personas con diabetes mellitus (Guía RECORD). Actualización 2021. Área de Conocimiento de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición (SEEN)
13. Demographic and clinical characteristics of a Spanish population of people living with type 1 diabetes who practice nonprofessional sports: The DIABESPORT survey
14. Information and consensus document for the detection and management of chronic kidney disease
15. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica
16. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
17. Executive summary: Position document: Evaluation and management of hypoglycemia in the patient with diabetes mellitus 2020. Diabetes Mellitus Working Group of the Spanish Society of Endocrinology and Nutrition
18. Resumen ejecutivo: Documento de posicionamiento: evaluación y manejo de la hipoglucemia en el paciente con diabetes mellitus 2020. Grupo de Trabajo de Diabetes Mellitus de la Sociedad Española de Endocrinología y Nutrición
19. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
20. Alterations of adult prefrontal circuits induced by early postnatal fluoxetine treatment mediated by 5-HT7 receptors
21. A comprehensive approach to type 2 diabetes mellitus – A recommendation document
22. Documento de abordaje integral de la diabetes tipo 2
23. Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score
24. Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
25. Impact of bariatric surgery on bone tissue
26. Impacto de la cirugía bariátrica en el tejido óseo
27. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
28. Plozasiran (ARO-APOC3), decreases APOC3 and triglycerides (TG) in patients with mixed dyslipidemia: MUIR final results
29. Plozasiran (ARO-APOC3), an investigational RNAI therapeutic, demonstrates profound and durable reductions in APOC-3 and triglycerides (TG) in patients with severe hypertriglyceridemia (SHTG), SHASTA-2 final results
30. Phenomenology and the Other: Phenomenology Facing the Twenty-First Century
31. Consensus on insulin treatment in type 2 diabetes
32. Consenso sobre tratamiento con insulina en la diabetes tipo 2
33. GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome
34. Ortega y la fenomenología. Diálogos con Javier San Martín
35. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period
36. RNAi Therapeutics for Diseases Involving Protein Aggregation: Fazirsiran for Alpha-1 Antitrypsin Deficiency-associated Liver Disease
37. Abstract 15751: Pharmacodynamic Effect of ARO-ANG3, an Investigational RNA Interference Targeting Hepatic Angiopoietin-like Protein 3, in Patients With Hypercholesterolemia
38. Abstract 12594: Pharmacodynamic Effect of ARO-APOC3, an Investigational Hepatocyte-targeted RNA Interference Therapeutic Targeting Apolipoprotein C3, in Patients With Hypertriglyceridemia and Multifactorial Chylomicronemia
39. The diabetic paradox: Bone mineral density and fracture in type 2 diabetes
40. Pharmacological Signature and Target Specificity of Inhibitory Circuits Formed by Martinotti Cells in the Mouse Barrel Cortex
41. GABAergic over-inhibition, a promising hypothesis for cognitive deficits in Down syndrome
42. Axonal GABAA receptors depolarize presynaptic terminals and facilitate transmitter release in cerebellar Purkinje cells
43. Belief and Affectivity. A Chapter of Philosophical Anthropology
44. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency
45. Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
46. Pharmacological Signature and Target Specificity of Inhibitory Circuits Formed by Martinotti Cells in the Mouse Barrel Cortex.
47. Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia
48. Molecular signature and target-specificity of inhibitory circuits formed by Martinotti cells in the mouse barrel cortex
49. Author response for 'Burosumab for the Treatment of Tumor-Induced Osteomalacia'
50. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.